Tirzepatide: a Targeted Advancement in OSA Management Among metabolic therapies, tirzepatide has generated particular interest and emerged as the most clinically advanced agent in this class owing to its dual mechanism of action
Almost There
If you're really watching your sugar intake, always ask for 'no added sugar' or 'no turbinado.' Sometimes I'll even ask for a scoop of greens to sneak in some extra nutrients without changing the taste much
Dosing: Daily subcutaneous injection Maximum dose: 3.0 mg/day Average weight loss (SCALE trial): 8% over 56 weeks List price: ~$1,349/mo FDA-approved for: Adults and adolescents 12+ with BMI 30 (or 27 with comorbidities) Zepbound (Tirzepatide) The 2023 Newcomer Zepbound, FDA-approved in November 2023, contains tirzepatide a dual GIP/GLP-1 receptor agonist
to lower the risk of heart attack or stroke in adults with type 2 diabetes and heart disease
PubMed, Miglis, Mitchell G., et al